Oncology is one of the most complex, costly, and emotionally challenging parts of healthcare. Too often, the system was not designed for people with cancer—and it shows. Patients fall through the cracks, providers face unnecessary barriers, and payers see costs rise, often without commensurate improvements in outcomes.

That’s why we launched Thyme Care five years ago. We built a model that, for the first time, aligns patients, providers, and payers around a single goal: better outcomes, lower costs, and an experience that feels more human.

We’ve shown it works. Today, Thyme Care has national partnerships with leading payers and providers. 8 million people have access to our model across all 50 states, and we manage more than $5 billion in oncology spend. The result: earlier interventions, fewer hospital visits, less provider burden, and patients who feel truly supported along the way.

Now, with the close of our $97M Series D backed by CVS Health® Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures,as well as new strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health Systemwe’re taking the next step: scaling what’s working, and unlocking new opportunities to fix what’s still broken.

Why this matters

This raise isn’t just about capital. It’s about validation from the people who know oncology best—payers, providers, employers, and health systems who see firsthand the impact of our model. They’re not betting on a concept. They’re doubling down on a proven approach that is already delivering at scale.

And we’re doing it for the people behind the statistics:

• The two million people who will be diagnosed with cancer this year.
• The women and younger adults increasingly affected by cancer.
• The patients who day in and day out are burdened by financial toxicity.

Our vision has been the same from day one: to transform the cancer care experience. And now we can execute with greater depth and breadth than ever before. 

What we’ve proven so far

Since 2020, we’ve shown that reshaping navigation and integrating it into broader oncology workflows can change the game:

• 90% of members report feeling more supported with Thyme Care.
• 72% of members proactively share updates via ePROs—nearly double the industry average.
  Members completing ePROs were 40% less likely to visit the ER and had 19% fewer hospital admissions.
• One oncology partner saved 2,000 hours of staff time in a year thanks to Thyme Care taking on coordination and admin burden.

Behind every data point is a real person. These metrics reflect lives changed, families supported, and providers freed up to focus on what matters most.

The people making it possible

Transformation takes more than vision. It takes people.

Our team shows up every day with compassion, urgency, and creativity. They meet patients in their hardest moments and find ways to make their journeys less overwhelming.

Our partners—oncologists, health plans, employers, hospitals, and life sciences leaders—trust us to be in the trenches with them, aligning incentives and delivering results together.

And our investors bring more than capital. They bring conviction and experience across the healthcare ecosystem, ensuring we scale responsibly and sustainably.

This community is the reason Thyme Care has moved from idea to national impact in just five years. I couldn’t be more grateful.

What’s next: Tackling the bigger breakpoints

We know the work isn’t done. There are still delays, denials, drug costs, and access barriers that frustrate patients and providers every day. With this raise, we’ll expand our reach and deepen our impact by:

• Accelerating with AI: AI isn’t a side project—it’s core to our mission. It powers earlier interventions, smarter affordability strategies, and more connected care.
  
  
• Reducing barriers to therapy: Streamlining approvals and aligning incentives so evidence-based care gets to patients faster, supporting adherence, managing side effects, and generating insights that improve future care.
  
  
• Improving drug affordability: Working with providers to make high-value, lower-cost drug decisions at the point of care.

Transformation doesn’t happen in silos. It requires every player in the oncology ecosystem to move in the same direction. Our role is to be the connective tissue that makes that movement possible.

Looking ahead

Every next step we take will honor our mission: to create a future where every single touchpoint in oncology care feels connected, supported, and aligned around the patient.

We’re not just building for today. We’re building the infrastructure for a generation of cancer care that is more proactive, more affordable, and more human.

And we’re just getting started.

— Robin Shah

Co-Founder & CEO, Thyme Care